PURPOSE: Nutritional status may influence quality of life and prognosis among pancreatic cancer patients, yet few studies describe measures of nutritional status during treatment. We evaluated the nutritional status of locally advanced pancreatic cancer (LAPC) patients undergoing chemoradiotherapy who received baseline nutritional assessment and counseling. METHODS: Fourteen newly diagnosed LAPC patients enrolled in phase I/II trials of capecitabine with concomitant radiotherapy were assessed for baseline clinical nutrition measures (body mass index, albumin, weight loss, total energy, and protein intake). Participants completed the Anorexia/Cachexia Subscale (A/CS) questionnaire at baseline and during the 6 weeks of treatment. We evaluated associations between baseline characteristics and subsequent A/CS scores with linear regression and changes in A/CS were assessed with the paired t test. RESULTS: We observed a statistically significant increase in mean A/CS between baseline [24.9, standard deviation (SD) = 9.7] and end of treatment (29.9, SD = 6.2). Controlling for baseline A/CS score, only weight loss greater than 5% of body weight over 1 month was associated with A/CS scores at 6 weeks (β = 10.558, standard error = 3.307, p value = 0.009) and mean A/CS scores during the last 3 weeks of treatment (β = 12.739, standard error = 2.251, p value = 0.001). CONCLUSIONS: After 6 weeks of chemoradiotherapy, LAPC patients reported a statistically significant improvement in appetite and weight concerns. Increases in AC/S scores were associated with higher baseline A/CS scores and weight loss of 5% or more during 1 month. Further research is needed to determine the impact of nutritional support during treatment, as improvements in this domain may impact LAPC patients' overall quality of life.
PURPOSE: Nutritional status may influence quality of life and prognosis among pancreatic cancerpatients, yet few studies describe measures of nutritional status during treatment. We evaluated the nutritional status of locally advanced pancreatic cancer (LAPC) patients undergoing chemoradiotherapy who received baseline nutritional assessment and counseling. METHODS: Fourteen newly diagnosed LAPCpatients enrolled in phase I/II trials of capecitabine with concomitant radiotherapy were assessed for baseline clinical nutrition measures (body mass index, albumin, weight loss, total energy, and protein intake). Participants completed the Anorexia/Cachexia Subscale (A/CS) questionnaire at baseline and during the 6 weeks of treatment. We evaluated associations between baseline characteristics and subsequent A/CS scores with linear regression and changes in A/CS were assessed with the paired t test. RESULTS: We observed a statistically significant increase in mean A/CS between baseline [24.9, standard deviation (SD) = 9.7] and end of treatment (29.9, SD = 6.2). Controlling for baseline A/CS score, only weight loss greater than 5% of body weight over 1 month was associated with A/CS scores at 6 weeks (β = 10.558, standard error = 3.307, p value = 0.009) and mean A/CS scores during the last 3 weeks of treatment (β = 12.739, standard error = 2.251, p value = 0.001). CONCLUSIONS: After 6 weeks of chemoradiotherapy, LAPCpatients reported a statistically significant improvement in appetite and weight concerns. Increases in AC/S scores were associated with higher baseline A/CS scores and weight loss of 5% or more during 1 month. Further research is needed to determine the impact of nutritional support during treatment, as improvements in this domain may impact LAPCpatients' overall quality of life.
Authors: J F Vansteenkiste; J E Vandebroek; K L Nackaerts; P Weynants; Y J Valcke; D A Verresen; R C Devogelaere; S A Marien; Y P Humblet; N L Dams Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: M Wasif Saif; Mohammaed A Eloubeidi; Suzanne Russo; Adam Steg; Jennifer Thornton; John Fiveash; Mark Carpenter; Carmello Blanquicett; Robert B Diasio; Martin R Johnson Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: Simone Gärtner; Janine Krüger; Ali A Aghdassi; Antje Steveling; Peter Simon; Markus M Lerch; Julia Mayerle Journal: Gastrointest Tumors Date: 2016-01-08
Authors: Asta Bye; Marit S Jordhøy; Grete Skjegstad; Oddlaug Ledsaak; Per Ole Iversen; Marianne Jensen Hjermstad Journal: Support Care Cancer Date: 2012-06-10 Impact factor: 3.603
Authors: Sally Wheelwright; Anne-Sophie Darlington; Jane B Hopkinson; Deborah Fitzsimmons; Alice White; Colin D Johnson Journal: Support Care Cancer Date: 2013-06-25 Impact factor: 3.603
Authors: Anna E Arthur; Ashley Delk; Wendy Demark-Wahnefried; John D Christein; Carlo Contreras; James A Posey; Selwyn Vickers; Robert Oster; Laura Q Rogers Journal: J Cancer Surviv Date: 2016-04-30 Impact factor: 4.442
Authors: Janine Krüger; Peter J Meffert; Lena J Vogt; Simone Gärtner; Antje Steveling; Matthias Kraft; Julia Mayerle; Markus M Lerch; Ali A Aghdassi Journal: PLoS One Date: 2016-11-18 Impact factor: 3.240
Authors: Taylor M Gilliland; Nicole Villafane-Ferriol; Kevin P Shah; Rohan M Shah; Hop S Tran Cao; Nader N Massarweh; Eric J Silberfein; Eugene A Choi; Cary Hsu; Amy L McElhany; Omar Barakat; William Fisher; George Van Buren Journal: Nutrients Date: 2017-03-07 Impact factor: 5.717
Authors: Kate Furness; Catherine E Huggins; Lauren Hanna; Mary Anne Silvers; Paul Cashin; Liang Low; Daniel Croagh; Terry P Haines Journal: BMC Cancer Date: 2018-11-29 Impact factor: 4.430
Authors: Andrew E Hendifar; Maria Q B Petzel; Teresa A Zimmers; Crystal S Denlinger; Lynn M Matrisian; Vincent J Picozzi; Lola Rahib Journal: Oncologist Date: 2018-12-27 Impact factor: 5.837